Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Free Cash Flow (2024 - 2025)

Prelude Therapeutics' Free Cash Flow history spans 2 years, with the latest figure at $23.1 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 215.35% year-over-year to $23.1 million; the TTM value through Dec 2025 reached -$56.4 million, up 45.22%, while the annual FY2025 figure was -$56.4 million, 45.22% up from the prior year.
  • Free Cash Flow for Q4 2025 was $23.1 million at Prelude Therapeutics, up from -$19.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $23.1 million in Q4 2025 and bottomed at -$34.3 million in Q1 2025.